Abhishek Koladiya

Abhishek Koladiya

Auto-generated profile, based on publicly available information

Abhishek Koladiya

Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2020 in F1000Research
Verified
Journal Article
Open access
PDF file
MKMiroslav Kratochvil
Miroslav Kratochvil
AKAbhishek Koladiya
Abhishek Koladiya
JVJiří Vondrášek
Jiří Vondrášek
EmbedSOM is a simple and fast dimensionality reduction algorithm, originally developed for its applications in single-cell cytometry data analysis. We present an updated version of EmbedSOM, viewed as an algorithm for landmark-directed embedding enrichment, and demonstrate that it works well even with manifold-learning techniques other than the self-organizing maps. Using this generalization, we introduce an inwards-growing variant of self-organizing maps that is designed to mitigate some earlier identified deficiencies of EmbedSOM output. Finally, we measure the performance of the generalized EmbedSOM, compare several variants of the algorithm that utilize different landmark-generating functions, and showcase the functionality on single-cell cytometry datasets from recent studies.

18 December 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
MKMiroslav Kratochvil
Miroslav Kratochvil
AKAbhishek Koladiya
Abhishek Koladiya
JVJiří Vondrášek
Jiří Vondrášek
EmbedSOM is a simple and fast dimensionality reduction algorithm, originally developed for its applications in single-cell cytometry data analysis. We present an updated version of EmbedSOM, viewed as an algorithm for landmark-based embedding enrichment, and demonstrate that it works well even with manifold-learning techniques other than the self-organizing maps. Using this generalization, we introduce an inwards-growing variant of self-organizing maps that is designed to mitigate some earlier identified deficiencies of EmbedSOM output. Finally, we measure the performance of the generalized EmbedSOM, compare several variants of the algorithm that utilize different landmark-generating functions, and showcase the functionality on single-cell cytometry datasets from recent studies.

14 May 2026 in Blood
Verified
Journal Article
Open access
YLYuxuan Liu
Yuxuan Liu
HJHaowen Jiang
Haowen Jiang
JLJingjing Liu
Jingjing Liu
JSJEAN EMMANUEL SARRY
JEAN EMMANUEL SARRY
MMMilton Merchant
Milton Merchant
KDKara L. Davis
Kara L. Davis
Relapse remains a major barrier to survival in B-cell acute lymphoblastic leukemia (B-ALL). Both activation of B-cell signaling pathways and increased glucose consumption have been linked to chemoresistance and relapse risk. In this study, we connect these observations by showing that B-ALL cells with active mTOR signaling, marked by high phosphorylated ribosomal protein S6 (pS6+), are glucose dependent. Isotope tracing confirms that pS6+ cells are highly glycolytic and rely on glucose for de novo nucleotide synthesis. Uridine, but not other purines or pyrimidines, rescue pS6+ cells from glucose deprivation, highlighting uridine as essential for survival. Active mammalian target of rapamycin (mTOR) signaling in pS6+ cells drives de novo pyrimidine synthesis by activating carbamoyl phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD), which catalyzes the initial steps of de novo pyrimidine synthesis. Inhibiting signaling abolishes glucose dependency and CAD phosphorylation. Primary pS6+ cells express high levels of pyrimidine synthesis proteins, including dihydroorotate dehydrogenase (DHODH), the rate-limiting enzyme in pyrimidine synthesis. Increased DHODH expression correlates with relapse and poor event-free survival. Most B-ALL molecular subtypes exhibit DHODH activity. BAY-2402234, a DHODH inhibitor, effectively kills pS6+ cells in vitro, with 50% inhibitory concentration values correlating with pS6 signaling strength across 14 xenografts derived from patients with B-ALL. In vivo, DHODH inhibition prolongs survival and reduces leukemia burden in pS6+ B-ALL models. Together, these findings link active signaling to pyrimidine dependency and relapse risk, highlighting DHODH inhibition as a promising therapeutic strategy for chemotherapy-resistant B-ALL.

26 July 2025 in bioRxiv
Verified
Preprint
Open access
AKAbhishek Koladiya
Abhishek Koladiya
ZGZinaida Good
Zinaida Good
SVSricharan Reddy Varra
Sricharan Reddy Varra
SBSean C Bendall
Sean C Bendall
KDKara L. Davis
Kara L. Davis
Single-cell and spatial proteomic technologies capture complementary biological information, yet no single platform can measure all modalities within the same cell. Most existing integration methods are optimized for transcriptomic data and rely on a large set of shared, strongly linked features, an assumption that often fails for low-dimensional proteomic modalities. We present CellFuse, a deep learning-based, modality-agnostic integration framework designed specifically for settings with limited feature overlap. CellFuse leverages supervised contrastive learning to learn a shared embedding space, enabling accurate cell type prediction and seamless integration across modalities and experimental conditions. Across a range of datasets including healthy PBMCs, bone marrow, CAR-T–treated lymphoma, and healthy and tumor tissues—CellFuse consistently outperforms existing methods in both integration quality and runtime efficiency. It maintains high accuracy even in the presence of missing markers and rare cell types, and performs robustly in cross-dataset comparisons, making it a powerful tool for scalable and high-fidelity single-cell data integration in basic and translational research.

15 August 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
HCHyunmin Cho
Hyunmin Cho
RSRuhi Sayana
Ruhi Sayana
AKAbhishek Koladiya
Abhishek Koladiya
PCPasqualina Colella
Pasqualina Colella
SCSangkyun Cho
Sangkyun Cho
NGNatalia Gomez-Ospina
Natalia Gomez-Ospina
Friedreich’s ataxia (FA) is a mitochondrial disease caused by frataxin deficiency that leads to progressive neurodegeneration and cardiomyopathy. Effective disease-modifying therapies remain limited. Here we show that myeloid cell replacement promotes neurological and cardiac recovery in FA mice through intercellular mitochondrial transfer. Donor-derived mitochondria are transferred from microglia and macrophages to central nervous system cells and cardiomyocytes, increasing oxidative phosphorylation and ATP synthesis gene expression and mitochondrial protein abundance. These molecular changes are accompanied by improved survival and growth in male and female mice and enhanced spontaneous locomotion, strength, coordination and cardiac and function in female mice. In cultured cells, mitochondrial transfer requires direct cell-cell contact and partially restores respiratory capacity in frataxin-deficient recipient cells, which exhibit enhanced mitochondrial uptake, suggesting disease-specific mechanisms that promote mitochondrial acquisition or retention. These findings identify mitochondrial transfer as a mechanism underlying the therapeutic effects of myeloid cell replacement and support hematopoietic transplantation for FA and other mitochondrial disorders.

2 June 2026 in Cancer Research
Verified
Journal Article
Open access
AKAbhishek Koladiya
Abhishek Koladiya
ZGZinaida Good
Zinaida Good
SVSricharan Reddy Varra
Sricharan Reddy Varra
PDPablo Domizi
Pablo Domizi
SBSean C. Bendall
Sean C. Bendall
KDKara L. Davis
Kara L. Davis
Analysis of tumors using single-cell and spatial modalities is critical to advance our understanding of cancer. The growth of technologies that enable these studies provides an increasing number of single cell datasets. Integrating such data across studies will increase the impact of individual studies and speed cancer research. Most existing integration approaches are tailored to transcriptomic data and assume large sets of shared features, an assumption that fails for lower dimensional proteomic measurements. Here, we developed CellFuse, a deep learning–based integration framework that unifies antibody-based proteomic datasets, including high-dimensional cytometry, cellular indexing of transcriptomes and epitopes by sequencing, and spatial proteomics data. Leveraging supervised contrastive learning, CellFuse learned a shared embedding space that enabled accurate cross-modality cell-type prediction and robust label transfer across tumor samples and experimental conditions. Applied to datasets spanning peripheral blood, bone marrow, and lymphoma, CellFuse consistently outperformed existing approaches in recovering clinically relevant populations, including rare malignant and immune subsets. In solid tumors, it reconstructed spatially resolved microenvironments, capturing interactions between malignant, stromal, and immune cells that correlated with treatment response. By enabling scalable, modality-agnostic integration, CellFuse provides a powerful tool to uncover prognostic cell states and delineate the architecture of the tumor–immune ecosystem with translational relevance, driving cancer discoveries. Significance: CellFuse is a supervised contrastive learning framework enabling accurate, scalable integration of single-cell proteomic and transcriptomic data, overcoming sparse marker overlap and differing distributions to improve analysis of single-cell data in cancer.